Brawn Biotech Shareholders Approve Key Resolutions at 40th AGM

Brawn Biotech Limited , a pharmaceutical company, held its 40th Annual General Meeting (AGM) on September 30, 2025, where shareholders approved several important resolutions. The meeting, conducted through video conferencing, saw active participation from shareholders and key company officials.

Key Resolutions Approved

Manager Re-appointment

Shareholders approved the re-appointment of Mr. Amit Kumar as the Manager (Key Managerial Personnel) of the company for an additional five-year term, from February 12, 2026, to February 11, 2031. Kumar, who holds a Post Graduate Diploma in Business Administration, brings over a decade of experience in operations and sales within the pharmaceutical industry to his role.

Corporate Document Update

In alignment with current regulations, shareholders approved the adoption of a new Memorandum of Association (MoA) in compliance with the Companies Act, 2013. This special resolution ensures that Brawn Biotech's corporate documents are up-to-date with the latest legal requirements. The company clarified that while the MoA was updated, there were no changes to the main objects of the company.

Financial Statement Adoption and Director Re-appointment

Other resolutions passed at the AGM included:

Adoption of the audited financial statements for the year ended March 31, 2025
Re-appointment of Mrs. Brij Bala Gupta, who retired by rotation and offered herself for re-appointment

Voting Results

The company reported strong shareholder support for all resolutions:

Resolution	Votes in Favor	Votes Against
Adoption of Financial Statements	1,027,976 (99.99%)	54 (0.01%)
Re-appointment of Mrs. Brij Bala Gupta	1,027,976 (99.99%)	54 (0.01%)
Re-appointment of Mr. Amit Kumar as Manager	1,027,976 (99.99%)	54 (0.01%)
Adoption of New Memorandum of Association	1,027,976 (99.99%)	54 (0.01%)

Meeting Details

The AGM, which began at 11:00 AM, concluded at 11:13 AM, with e-voting remaining open for an additional 30 minutes. Mr. Brij Raj Gupta presided over the meeting as Chairman.

Brawn Biotech's commitment to transparency and compliance was evident in their prompt disclosure of the AGM proceedings and voting results to the Bombay Stock Exchange, in line with regulatory requirements.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
+4.06%	-3.61%	-0.55%	+21.58%	-3.19%	-4.99%

Brawn Biotech Limited , a pharmaceutical company, has reported a significant turnaround in its financial performance for the first quarter. The company's board approved the unaudited financial results for the quarter ended June 30, revealing a profit of Rs 23.60 lacs, a marked improvement from previous losses.

Financial Highlights

Profit: Rs 23.60 lacs, compared to a loss of Rs 49.44 lacs in the previous quarter and Rs 52.81 lacs loss in the same quarter last year.
Revenue: Increased substantially to Rs 579.77 lacs from Rs 225.93 lacs in the previous quarter and Rs 406.41 lacs in Q1 of the previous year.
Total Comprehensive Income: Rs 26.80 lacs, up from a loss of Rs 49.52 lacs in the prior quarter.
Earnings Per Share (EPS): Improved to Rs 0.89 from negative Rs 1.65 in the previous quarter.

Performance Analysis

The company's financial results demonstrate a remarkable recovery, with revenue more than doubling compared to the previous quarter. This significant increase in revenue, coupled with effective cost management, has enabled Brawn Biotech to turn its losses into profits.

Key Financial Data

Particulars (Rs. in Lacs)	Q1 (30-Jun)	Q4 (31-Mar)	Q1 (30-Jun) Previous Year
Revenue from Operations	579.77	225.93	406.41
Total Revenue	588.86	235.04	406.41
Total Expenses	565.26	284.49	459.23
Profit/(Loss)	23.60	(49.44)	(52.81)
EPS (Basic & Diluted)	0.89	(1.65)	(1.83)

Management Commentary

While specific management comments were not provided, the financial results reflect a positive trend in the company's operations. The significant increase in revenue and the shift from loss to profit indicate improved market conditions and potentially successful business strategies implemented by Brawn Biotech.

Auditor's Review

The company's statutory auditor, Rajiv Udai & Associates, conducted a limited review of the financial results for the quarter ended June 30. The auditors stated that nothing has come to their attention that causes them to believe that the financial results do not present a true and fair view in accordance with applicable accounting standards and SEBI regulations.

Conclusion

Brawn Biotech Limited's Q1 results showcase a strong recovery, with the company successfully turning around its financial performance. The substantial increase in revenue and the return to profitability are positive indicators for the company's shareholders and stakeholders. As the pharmaceutical sector continues to be a critical industry, Brawn Biotech's improved performance may signal potential growth opportunities in the coming quarters.